Results 171 to 180 of about 131,252 (300)

From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems

Chemistry – A European Journal, EarlyView.
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui, Tianlu Wang, Yaoyu Han, Yun Huang, Tien‐Hung Lan, Yunbin Zhou   +5 more
wiley   +1 more source

Identification of a Class of Novel, Selective, Structurally Distinct GluN2A Negative Allosteric Modulators Through Virtual Screening. [PDF]

ChemMedChem
Viturro CMM, Neff RA, Bembenek SD, Cid JM.   +3 more
europepmc   +1 more source

Bidirectional control of vesicular GABA release, LTP, and amotivation by GluN2D-selective allosteric modulators and ketamine. [PDF]

Cell Rep
Oláh VJ, Witteveen IF, Banke TG, Leahy AM, Keable R, Perszyk RE, Khayat CT, Nguyen TT, Bixler BJ, Ghinger FG, Vullhorst D, Yook Y, Myers SJ, Ullman EZ, Zhang J, Xing H, Traynelis JF, Diaz ES, Kim S, Boraschi S, Akins NS, Liu KH, Westhuyzen AV, Yang Y, Camp CR, Buonanno A, Hall RA, Zheng JQ, Liotta DC, Kennedy MJ, Roche KW, Gourley SL, Yuan H, Rowan MJM, Traynelis SF.   +34 more
europepmc   +1 more source

Microtubule Destabilizing Kinesins: A Historical Perspective and Thoughts for the Future

Cytoskeleton, EarlyView.
ABSTRACT The microtubule cytoskeleton plays critical roles in multiple cellular processes such as mitotic spindle assembly and chromosome segregation. Cells contain a number of microtubule‐associated proteins that regulate microtubule dynamics both temporally and spatially in cells. The microtubule depolymerizing kinesins include members of the Kinesin‐
Claire E. Walczak
wiley   +1 more source

Molecular pharmacology of mGlu_7/8 heterodimers reveals unique properties of orthosteric agonists and positive allosteric modulators. [PDF]

Mol Pharmacol
Ferranti AS, Noh Y, Lei X, Lin X, Bungard JD, Asher WB, Javitch JA, Niswender CM.   +7 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Allosteric Modulators of Drug Targets [PDF]

Journal of Medicinal Chemistry, 2018
openaire   +2 more sources

Deep learning reveals endogenous sterols as allosteric modulators of the GPCR-Gα interface. [PDF]

Elife
Mohanty SK, Mittal A, Farooqi N, Gaur A, Duari S, Solanki S, Sharma AK, Arora S, Kumar S, Gautam V, Dixit NK, Subramanian K, Ghosh TS, Sengupta D, Gupta SK, Murugan AN, Sharma D, Ahuja G.   +17 more
europepmc   +1 more source

Cenobamate use in super‐refractory status epilepticus: A report of three cases

Epileptic Disorders, EarlyView.
Abstract Objectives Super‐refractory status epilepticus (SRSE) is a neurological emergency with high morbidity and mortality. Cenobamate, a novel antiseizure medication, may be helpful in managing SRSE, but evidence is limited. Methods This retrospective case series reports the use of cenobamate as add‐on therapy in the management of three cases of ...
Marina Romozzi, Juan Luis Alcala‐Zermeno, Antonio Funcis, Federico Tosto, Marta Piccioli, Luigi Francesco Iannone, Riccardo Maviglia, Masahito Katsuki, Yasuhiko Matsumori, Paolo Calabresi, Raffaele Iorio, Catello Vollono   +11 more
wiley   +1 more source

Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B. [PDF]

Int J Mol Sci
Pérez-Carmona N, Cubero E, Ruano A, Pons-Vizcarra M, Delgado A, Trapero A, Reves M, Rodríguez-Pascau L, Taylor J, Martinell M, Barril X, García-Collazo AM.   +11 more
europepmc   +1 more source